You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)子公司藥明海德投資2.4億美元在愛爾蘭建立疫苗生產基地
格隆匯 11-23 09:31

全球領先的開放式生物製藥技術平台公司藥明生物(WuXi Biologics, 2269.HK)11月22日宣佈其從事疫苗合同定製研發生產(CDMO)服務的子公司藥明海德將投資2.4億美元在愛爾蘭新建一座疫苗生產基地,這是為藥明海德今年早些時候簽訂合同期長達20年的合作意向書(LOI)而籌建。

左起:愛爾蘭投資發展局(IDA)東北部區域發展經理James Boyle,藥明生物全球工程副總裁George R. Skillin,藥明海德高級副總裁蔡德良,海利生物董事長兼藥明海德董事張海明,中國駐愛爾蘭大使何向東,藥明生物首席執行官兼藥明海德董事長陳智勝,藥明生物董事長兼藥明海德董事李革,愛爾蘭商業、企業與創新部部長Heather Humphreys TD,IDA歐洲及高成長市場全球主管Eileen Sharpe,藥明生物副總裁兼愛爾蘭基地負責人Brendan McGrath

根據合作意向書,藥明海德將新建一座集疫苗原液(藥明生物十五廠,MFG15)及製劑(藥明生物製劑五廠,DP5)生產、質量控制(QC)實驗室於一體的生產基地,專門為一家大型跨國製藥企業的一款疫苗產品提供生產服務並供應全球市場。該疫苗生產基地將位於藥明生物愛爾蘭園區內,毗鄰藥明生物正在建設的全球領先生物製藥“未來工廠”生產基地,後者預計將於2021年投入商業化生產。

藥明生物愛爾蘭“未來工廠”基地建設進展

愛爾蘭商業、企業與創新部部長Heather Humphreys TD女士表示:“我很高興宣佈此次投資將新增200個高新技術工作崗位,這也是繼去年藥明生物愛爾蘭投資創造400個工作崗位後的又一重要喜訊,再次彰顯愛爾蘭地區具有強勁的投資吸引力。”

愛爾蘭投資發展局(IDA)歐洲及高成長市場全球主管Eileen Sharpe女士表示:“此次藥明生物在敦多克基地宣佈的第二筆重大投資對於促進本地發展具有重要戰略意義。作為愛爾蘭首個疫苗合同定製研發生產基地,該投資項目將極大地賦能本地生命科學生態圈,提升愛爾蘭在該領域的高價值生產製造能力。”

藥明生物首席執行官兼藥明海德董事長陳智勝博士表示:“我們非常高興在愛爾蘭投資打造首個疫苗生產基地賦能合作伙伴。由於生產工藝高度複雜、分析檢測方法繁多以及法規標準嚴格,疫苗生產難度頗高,生產過程中的工藝質量控制對確保產品質量也至關重要。此項投資開創了疫苗行業全新合作模式,進一步證明藥明生物卓越的技術實力、領先的質量體系和商業化生產能力,將助力愛爾蘭當地生物製藥產業發展。藥明生物將攜手藥明海德繼續通過公司健全強大的全球供應鏈網絡,賦能合作伙伴生產高質量生物製品,造福廣大病患。”

中國駐愛爾蘭大使何向東先生、藥明生物董事長兼藥明海德董事李革博士、海利生物董事長兼藥明海德董事張海明先生,愛爾蘭當地政府官員及媒體記者等近百人出席了在愛爾蘭舉行的活動儀式。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account